Comparing bimatoprost and travoprost in black Americans

Noecker, Robert J.; Earl, Melissa; Mundorf, Thomas K.; Silverstein, Steven; Phillips, Michael P

doi:10.1185/030079906x148418

Cited by 24 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,3 Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. 7 However, Noecker et al 10,11 compared bimatoprost with travoprost in African Americans with glaucoma or ocular hypertension (OHT), and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.…”

Section: Introductionmentioning

confidence: 98%

Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective, Randomized Study

Macky

2010

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective, Randomized Study

Macky

2010

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…After looking through a large collection of papers of clinical trials on IOP reductions and on comparing drugs for type-2 diabetes, we believe that the above three categories cover a significant proportion of statistical information (e.g., [4,7,15,21,30,32,34,37,40], etc).…”

Section: Obtaining Sampling Distributions From Clinical Trialsmentioning

confidence: 99%

“…A huge number of clinical trials have been carried out in the last few decades and new trials are constantly being designed and implemented. For example, many clinical trials have been carried out to investigate issues including: the intraocular pressure (IOP) lowering efficacy of drugs, such as travoprost, bimatoprost, timolol, and latanoprost, (e.g., [4,7,15,21,30,32,34,37,40]); oral medications for adults with Type-2 diabetes (e.g., [3,9,27,29,35,41]); the neurocognitive outcomes after off-pump versus on-pump coronary revascularisation (e.g., [14,25,26,31,43]). …”

Section: Introductionmentioning

confidence: 99%

An XML Based Framework for Merging Incomplete and Inconsistent Statistical Information from Clinical Trials

Liu

Hunter

et al. 2010

Soft Computing in XML Data Management

View full text Add to dashboard Cite

Abstract. Meta-analysis is a vital task for systematically summarizing statistical results from clinical trials that are carried out to compare the effect of one medication (or other treatment) against another. Currently, most meta-analysis activities are done by manually pooling data. This is a very time consuming and expensive task. An automated or even semi-automated tool that can support some of the processes underlying meta-analysis is greatly needed. Furthermore, statistical results from clinical trials are usually represented as sampling distributions (i.e., with the mean value and the SEM). When collecting statistical information from reports on clinical trials, not all reports contain full statistical information (i.e., some do not provide SEMs) whilst traditional meta-analysis excludes trials reports that contain incomplete information, which inevitably ignores many trials that could be valuable. Furthermore, some trials results can be significantly inconsistent with the rest of trials that address the same problem. Therefore, highlighting (resp. removing) such inconsistencies is also very important to reveal (resp. reduce) any potential flaws in some of the trials results. In this paper, we aim to design and develop a framework that tackles the above three issues. We first present an XML-based merging framework that aims to merge statistical information automatically with the potential to add a component to extract clinical trials information automatically. This framework shall consider any valid clinical trial including trials with partial information. We then develop a method to analyze inconsistencies among a collection of clinical trials and if necessary to exclude any trials that are deemed to be illegible. Finally, we use two sets of clinical trials, trials on Type 2 diabetes and on neurocognitive outcomes after off-pump versus on-pump coronary revascularisation, to illustrate our framework.

show abstract

“…Bimatoprost was superior in IOP lowering to travoprost only during the daytime (0800 and 1200 hours time-points), but latanoprost and travoprost were comparable at all time points (P # 0.82). 88 An industry-sponsored meta-analysis 90 of travoprost vs latanoprost (15 trials, n = 1098), 57,68,85,93,95,96,[98][99][100] travoprost vs bimatoprost (8 trials, n = 714), 57,85,87,93,95,96,101,102 and latanoprost vs bimatoprost (8 trials, n = 943) 57,64,85,86,93,95,96,103 found similar efficacy among the three PGAs. Studies comparing the PGA to other non-PGA glaucoma treatments, nonrandomized, dose-finding or cross-over trials, and short-term evaluations (less than 3 months) were excluded, although a trial evaluating timolol plus travoprost versus timolol alone, 100 was included indicating that the PGA effect has the same relative effect as if it were compared with no treatment.…”

mentioning

confidence: 99%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

Comparing bimatoprost and travoprost in black Americans

Abstract: Bimatoprost and travoprost each effectively lowered IOP in this population of black patients. More patients achieved clinically relevant IOP reductions with bimatoprost.

Cited by 24 publications

References 10 publications

Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective, Randomized Study

Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective, Randomized Study

An XML Based Framework for Merging Incomplete and Inconsistent Statistical Information from Clinical Trials

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Contact Info

Product

Resources

About